Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
29 avr. 2024 09h00 HE
|
Ceapro Inc.
– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and...
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
09 avr. 2024 09h15 HE
|
Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
28 mars 2024 07h55 HE
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
28 mars 2024 07h55 HE
|
Ceapro Inc.
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 mars 2024 08h05 HE
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12 mars 2024 14h10 HE
|
Ceapro Inc.; Aeterna Zentaris Inc.
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12 mars 2024 14h10 HE
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
With Extensive Two-Year Revenue Growth, ValueSelling Associates is Selected to Inc. Magazine’s List of the Pacific Region’s Fastest-Growing Private Companies
28 févr. 2024 13h09 HE
|
ValueSelling Associates, Inc.
ValueSelling Associates has been selected to the Inc. 5000 Regionals Pacific list, showcasing the fastest-growing Pacific private companies.
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
26 févr. 2024 07h30 HE
|
Aeterna Zentaris Inc
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
26 févr. 2024 07h30 HE
|
Ceapro Inc.
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...